Serina Therapeutics Inc
SER2.370USD
-0.090-3.64%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
24.99M시가총액
손실P/E TTM
자세한 내용은 Serina Therapeutics Inc 회사
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Serina Therapeutics Inc 정보
종목 코드 SER
회사 이름Serina Therapeutics Inc
상장일Nov 29, 2018
CEOLedger (Steven)
직원 수12
유형Ordinary Share
회계 연도 종료Nov 29
주소601 Genome Way,
도시HUNTSVILLE
증권 거래소NASDAQ OMX – NASDAQ Basic Amex
국가United States of America
우편 번호35806
전화12563279630
웹사이트https://serinatherapeutics.com/
종목 코드 SER
상장일Nov 29, 2018
CEOLedger (Steven)
Serina Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Independent Director
Independent Director
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
수익 분석
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
United States
0.00
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sat, Nov 15
마지막 업데이트: Sat, Nov 15
주주
주주 유형
주주
주주
비율
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
기타
51.65%
주주
주주
비율
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
기타
51.65%
주주 유형
주주
비율
Corporation
39.12%
Individual Investor
8.18%
Investment Advisor
2.92%
Hedge Fund
0.78%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.02%
기타
48.43%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
56
461.23K
4.33%
-32.35K
2025Q3
56
464.13K
4.40%
+21.47K
2025Q2
59
6.70M
67.24%
+256.13K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Juvenescence Ltd
3.27M
30.64%
--
--
Sep 17, 2025
Puffinus L.P.
904.88K
8.49%
--
--
Sep 17, 2025
McMillan (Helen w)
708.61K
6.64%
-133.79K
-15.88%
Sep 17, 2025
The Vanguard Group, Inc.
180.01K
1.69%
+29.39K
+19.51%
Sep 30, 2025
Ledger (Steven A)
95.73K
0.9%
-227.93K
-70.42%
Sep 17, 2025
Broadwood Capital, Inc.
83.19K
0.78%
-2.02K
-2.38%
Sep 30, 2025
Waverly Advisors, LLC
67.49K
0.63%
--
--
Sep 30, 2025
Bailey (Gregory Hugh)
67.24K
0.63%
--
--
Sep 17, 2025
Geode Capital Management, L.L.C.
29.61K
0.28%
+724.00
+2.51%
Sep 30, 2025
Linscomb & Williams, Inc.
18.80K
0.18%
+18.80K
--
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
비율0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
날짜
배당락일
유형
비율
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
